It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Metabolic regulation occurs through precise control of enzyme activity. Allomorphy is a post-translational fine control mechanism where the catalytic rate is governed by a conformational switch that shifts the enzyme population between forms with different activities. β-Phosphoglucomutase (βPGM) uses allomorphy in the catalysis of isomerisation of β-glucose 1-phosphate to glucose 6-phosphate via β-glucose 1,6-bisphosphate. Herein, we describe structural and biophysical approaches to reveal its allomorphic regulatory mechanism. Binding of the full allomorphic activator β-glucose 1,6-bisphosphate stimulates enzyme closure, progressing through NAC I and NAC III conformers. Prior to phosphoryl transfer, loops positioned on the cap and core domains are brought into close proximity, modulating the environment of a key proline residue. Hence accelerated isomerisation, likely via a twisted anti/C4-endo transition state, leads to the rapid predominance of active cis-P βPGM. In contrast, binding of the partial allomorphic activator fructose 1,6-bisphosphate arrests βPGM at a NAC I conformation and phosphoryl transfer to both cis-P βPGM and trans-P βPGM occurs slowly. Thus, allomorphy allows a rapid response to changes in food supply while not otherwise impacting substantially on levels of important metabolites.
A structural study shows that the enzyme βPGM uses an allomorphically controlled switch that accelerates proline isomerisation to alleviate the wastage of valuable metabolites while allowing the organism to react quickly to changes in food supply.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Sheffield, School of Biosciences, Sheffield, UK (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262); St. Jude Children’s Research Hospital, Department of Structural Biology, Memphis, USA (GRID:grid.240871.8) (ISNI:0000 0001 0224 711X)
2 University of Sheffield, School of Biosciences, Sheffield, UK (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262); The University of Manchester, Manchester Institute of Biotechnology and Department of Chemistry, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407)
3 University of Sheffield, School of Biosciences, Sheffield, UK (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262); Patterson Building, Cancer Research UK, Manchester Institute, Manchester, UK (GRID:grid.11485.39) (ISNI:0000 0004 0422 0975)
4 University of Sheffield, School of Biosciences, Sheffield, UK (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262); University of Bern, Department of Chemistry, Biochemistry and Pharmacy, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
5 The University of Manchester, Manchester Institute of Biotechnology and Department of Chemistry, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407)
6 University of Sheffield, School of Biosciences, Sheffield, UK (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262)